Smart Tech AI Can Now Analyze Your Mammograms to Predict Risk of Heart Disease
Source: Press release
ESC
3 min Reading Time
A new study shows that AI can be used to evaluate the build-up of calcium deposits in the breast arteries from X-ray mammography scans that are used in routine breast cancer screening.
The study shows that AI can be used to assess the build-up of calcium deposits in the arteries of the breast from the standard X-ray mammography scans that are currently used in routine breast cancer screening.
(Source: ESC)
Sophia Antipolis/France – The risk of serious or fatal heart disease can be predicted with artificial intelligence (AI) analysis of mammograms, according to research published in the European Heart Journal.
The study shows that AI can be used to assess the build-up of calcium deposits in the arteries of the breast from the standard X-ray mammography scans that are currently used in routine breast cancer screening.
Researchers say this technique could help the disproportionate number of women who have undiagnosed and untreated cardiovascular disease.
The study is by a team of researchers led by Dr. Hari Trivedi from Emory University, Atlanta, USA. He said: “Heart disease is the leading cause of death in women worldwide, yet women are consistently underdiagnosed and undertreated compared to men.
“Mammograms, which women already attend for breast cancer screening, can also reveal calcium deposits in breast arteries and this is linked to heart disease. We wanted to test whether AI could use this to identify women at risk of cardiovascular disease at no extra cost or inconvenience.”
The study included 123,762 women who had taken part in breast screening but had no known cardiovascular disease. Researchers used AI to analyze the amount of calcium deposit in the arteries of the breast tissue. This ‘arterial calcification’ is known to be a sign that the arteries are becoming hardened, and indicates a higher risk of conditions such as heart attack, heart failure stroke, and death. The amount of arterial calcification in the women’s breast tissue was categorized as severe, moderate, mild or absent.
Researchers compared this categorization with information on whether the women went on to develop serious cardiovascular disease, including stroke, heart attack or death from cardiovascular disease. They found that women with mild calcification were around 30 % more likely to suffer serious cardiovascular disease compared to women with no calcification. In women with moderate calcification, the risk was more than 70 % higher and in women with severe calcification, the risk was two to three times higher.
Dr Trivedi said: “We found that the more calcium visible in the breast arteries on a mammogram, the higher a woman's risk of a serious heart event such as a heart attack, stroke or heart failure. This was true even in younger women under the age of 50 a group often considered low-risk and held up after accounting for other risk factors like diabetes and smoking. This is the largest study of its kind and covers multiple races and across two major US health systems.”
“For women, this means a mammogram you're already having could also provide important information about your heart health prompting a conversation with your doctor about preventive steps such as cholesterol testing or medication. For clinicians, it offers a practical way to identify women at cardiovascular risk who are currently being missed.
“Policymakers could consider integrating this into existing mammography programs, potentially reaching tens of millions of women annually without any additional infrastructure. The main steps needed are integrating the AI tool into existing imaging workflows and establishing clear guidelines for notifying patients and doctors. We are now planning a clinical trial designed to test these steps.”
In an accompanying editorial Professor Lori B. Daniels from University of California, San Diego, USA, said: “Two-thirds of women aged 50–69 in the European Union reported a mammogram within the prior 2 years, and in the USA, nearly 70 % of women aged 45 years and older were up to date with mammography according to American Cancer Society screening guidelines. In contrast, <40 % of women report knowing their cholesterol levels.
“Breast arterial calcification (BAC) has the potential to reframe this mismatch, leveraging a widely adopted cancer-screening platform to identify cardiovascular risk in women who may not otherwise engage with prevention.
“[…] Dapamede et al. provide compelling evidence that AI-quantified Bac is an independent marker of cardiovascular risk and mortality, with a standardized mm2 metric that supports implementation. Regardless of the reporting metric ultimately adopted, it is time to shift BAC from observation to implementation, leveraging a touchpoint women already trust, to advance prevention for what remains the leading cause of death among women.”
Date: 08.12.2025
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.